Investigating a genetic variant's impact on hearing in the inner ear
Official title: Effects of the TECTB-C225Y Variant in the Inner Ear
Funded at Harvard Medical School · NIH-11062794 · Data updated 2026-11-12
This study is looking at how a specific gene change affects hearing by using mice that have this change, and it aims to help us understand hearing loss better so we can find new ways to treat it.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Harvard Medical School NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 30, 2024 |
| Project end | September 29, 2026 |
| Funding year | 2024 |
| Award (this year) | $36,983 |
| NIH project number | 1F31DC021855-01A1 |
| Project ID | NIH-11062794 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with a family history of autosomal-dominant hearing loss, particularly those with the TECTB-C225Y variant.
✕Less likely to help
Patients with hearing loss not linked to genetic factors or those without the TECTB-C225Y variant may not benefit from this research.
What this research studies
This research focuses on understanding how a specific genetic variant, TECTB-C225Y, affects hearing function. Using a mouse model that mimics this genetic mutation, researchers will assess auditory function through various tests, including auditory brainstem responses (ABR) and distortion product otoacoustic emissions (DPOAE). The study aims to characterize the hearing impairment associated with this variant and explore its underlying mechanisms, which could lead to new therapeutic strategies for hearing loss.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment options for patients with genetic hearing loss.
How similar studies have gone: Previous research has shown success in using genetic mouse models to study hearing loss, indicating that this approach is promising.
Where this research is happening
-
Harvard Medical School
Boston, United States Active
Researchers
- Principal investigator: Hale, Evan Brown — Harvard Medical School
- Study coordinator: Hale, Evan Brown
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.